Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke

Affordable Access

Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke

BioMed Central
Publication Date
Jul 17, 2006
  • Biology
  • Medicine


WNL205507 102..103 DOI 10.1212/WNL.0b013e3182a94f3c 2013;81;e102-e105 Neurology Dominic Hovsepian and Steven Karceski Stroke, tPA, and physician decision-making This information is current as of September 23, 2013 located on the World Wide Web at: The online version of this article, along with updated information and services, is Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X. since 1951, it is now a weekly with 48 issues per year. Copyright © 2013 American Academy of ® is the official journal of the American Academy of Neurology. Published continuouslyNeurology PATIENT PAGE Section Editors David C. Spencer, MD Steven Karceski, MD Dominic Hovsepian, BS Steven Karceski, MD Stroke, tPA, and physician decision-making WHATDID THERESEARCHERSSTUDY? Intravenous tissue plasminogen activator (IV tPA) is a protein that is used to break up blood clots. A blood clot that forms in an artery can block the flow of blood “downstream.” Areas of brain that rely on the now-blocked blood vessel become starved for oxygen. When a part of the brain is starved for oxygen, it is called ischemia or a stroke. The area of brain where the stroke occurs de- termines the resultant neurologic problems. For instance, if the stroke occurs in a region of brain that controls movement, the person becomes weak. When a stroke happens, the use of tPA can open the blood vessel and restore proper blood flow to the brain. Treatment with IV tPA can minimize the damage from a stroke by allowing blood and oxygen to reach its destination. Stroke is a common neuro- logic condition. It is estimated that stroke occurs in 2.5%–2.7% of people living in the United States or one of its colonies (data from 2006 to 2010: the Centers for Disease Control and Prevention1). Sur- prisingly, fewer than 5% of patients with ischemic stroke receive treatment with IV tPA.2 Many factors may affect the use of tPA. For instance, tPA mu

Report this publication


Seen <100 times